PSG5
Pregnancy-specific beta-1-glycoprotein 5
Also known as: FL-NCA-3, PSG, PSG5_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q15238
- Gene
- PSG5
- Ensembl
- ENSG00000204941
- Chromosome
- 19
- Canonical length
- 335 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in female reproductive system
OverviewNCBI Gene
The human pregnancy-specific glycoproteins (PSGs) are a group of molecules that are mainly produced by the placental syncytiotrophoblasts during pregnancy. PSGs comprise a subgroup of the carcinoembryonic antigen (CEA) family, which belongs to the immunoglobulin superfamily. For additional general information about the PSG gene family, see PSG1 (MIM 176390).[supplied by OMIM, Oct 2009]
Canonical amino-acid sequenceUniProt
335 residues, UniProt reviewed canonical sequence.
>Q15238|PSG5
1 MGPLSAPPCT QHITWKGLLL TASLLNFWNL PITAQVTIEA LPPKVSEGKD VLLLVHNLPQ
61 NLAGYIWYKG QLMDLYHYIT SYVVDGQINI YGPAYTGRET VYSNASLLIQ NVTREDAGSY
121 TLHIIKRGDR TRGVTGYFTF NLYLKLPKPY ITINNSKPRE NKDVLAFTCE PKSENYTYIW
181 WLNGQSLPVS PRVKRPIENR ILILPSVTRN ETGPYECEIR DRDGGMRSDP VTLNVLYGPD
241 LPSIYPSFTY YRSGENLYLS CFAESNPPAE YFWTINGKFQ QSGQKLSIPQ ITTKHRGLYT
301 CSVRNSATGK ESSKSMTVEV SAPSGIGRLP LLNPILocalizationUniProt · AlphaFold · HPA
Whether an antibody against PSG5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 106 nTPM
Expression across tissuesHPA
Tissue
- placenta: 106 nTPM
- smooth muscle: 0.8 nTPM
- kidney: 0.5 nTPM
- skin: 0.5 nTPM
- parathyroid gland: 0.3 nTPM
- retina: 0.3 nTPM
Single-cell type
- syncytiotrophoblasts: 1,020 nCPM
- migrating cytotrophoblasts: 63 nCPM
- extravillous trophoblasts: 35 nCPM
- retinal bipolar cells: 9.6 nCPM
- epicardial cells: 6.8 nCPM
- adipocytes: 3.1 nCPM
Immune cell
- basophil: 0.3 nTPM
- neutrophil: 0.2 nTPM
- naive B-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- cerebellum: 5.9 nTPM
- white matter: 3.4 nTPM
- cerebral cortex: 3.3 nTPM
- basal ganglia: 3.1 nTPM
- amygdala: 2.8 nTPM
- hippocampal formation: 2.8 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.9
- gnomAD pLI
- 0
- gnomAD missense Z
- -3.76
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PSG5 as an antibody target. Whether an autoantibody or antibody against PSG5 could matter depends on whether native PSG5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PSG5 is annotated as secreted, so native PSG5 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PSG5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...